Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation

scientific article published on 2 August 2007

Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.EJPB.2007.07.009
P698PubMed publication ID17904340
P5875ResearchGate publication ID5941258

P50authorSeulki LeeQ67139983
P2093author name stringMin Jung Kwon
Kang Choon Lee
Yu Seok Youn
Su Young Chae
Han Jong Shin
P433issue3
P407language of work or nameEnglishQ1860
P304page(s)667-675
P577publication date2007-08-02
P1433published inEuropean Journal of Pharmaceutics and BiopharmaceuticsQ5412740
P1476titleImproved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation
P478volume68

Reverse relations

cites work (P2860)
Q47390545A 4-arm polyethylene glycol derivative conjugated with exendin-4 peptide and palmitylamine having dual-function of size-increase and albumin-binding for long hypoglycemic action
Q34426261A silica-based pH-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1
Q37718748Enhanced hypoglycemic effect of biotin-modified liposomes loading insulin: effect of formulation variables, intracellular trafficking, and cytotoxicity
Q38628696Glucagon-Like Peptide-1 Formulation--the Present and Future Development in Diabetes Treatment
Q50048017Glucagon-like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities Beyond Type 2 Diabetes
Q42557469Glucagon-like peptide-1 functionalized PEG hydrogels promote survival and function of encapsulated pancreatic beta-cells
Q39790895In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy.
Q42318066Mechanism of hepatic targeting via oral administration of DSPE-PEG-cholic acid-modified nanoliposomes
Q36127715Oral Delivery of Pentameric Glucagon-Like Peptide-1 by Recombinant Lactobacillus in Diabetic Rats
Q27023585Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control?
Q38210847Oral peptide and protein delivery: intestinal obstacles and commercial prospects
Q38223053Orally active-targeted drug delivery systems for proteins and peptides
Q34618222Permeation of insulin, calcitonin and exenatide across Caco-2 monolayers: measurement using a rapid, 3-day system
Q38268308Physicochemical and formulation developability assessment for therapeutic peptide delivery--a primer

Search more.